Safety of guselkumab in patients with plaque psoriasis through 2 years: a pooled analysis from VOYAGE 1 and VOYAGE 2

被引：0
|
作者：
Reich, K. [1 ,2 ]
Papp, K. [3 ]
Armstrong, A. W. [4 ]
Wasfi, Y. [5 ]
Jiang, G. [5 ]
Shen, Y-K. [5 ]
Randazzo, B. [5 ]
Song, M. [5 ]
Kimball, A. B. [6 ]
机构：
[1] Dermatol Hamburg, Hamburg, Germany
[2] SCIderm Res Inst, Hamburg, Germany
[3] K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[4] Univ Southern Calif, Los Angeles, CA USA
[5] Janssen Res & Dev LLC, Spring House, PA USA
[6] Beth Israel Deaconess Med Ctr Inc, Boston, MA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P103
引用
收藏
页码：E297 / E297
页数：1
相关论文
共 50 条
  • [31] Consistency of response across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Armstrong, April W.
    Foley, Peter
    Shen, Yaung-Kaung
    Kimball, Alexa B.
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB83 - AB83
  • [32] Comparable and consistent efficacy responses with up to 3 years of gusellcumab treatment in patients with moderate-to-severe plaque psoriasis regardless of prior treatment: pooled analysis from the VOYAGE i and VOYAGE 2 trials
    Gordon, K.
    Guenther, L.
    Pinter, A.
    Choe, Y. -B.
    Song, M.
    Li, S.
    Fakharzadeh, S.
    Shen, Y. -K.
    Tsai, T. -F.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 32 - 32
  • [33] Experience in patients with a history of malignancy through 3 years of continuous treatment with guselkumab in the VOYAGE 1 and 2 trials
    Blauvelt, A.
    Papp, K. A.
    Ho, V.
    Ghoreschi, K.
    Kim, B. S.
    Shen, Y-K.
    Ramachandran, P.
    Song, M.
    Uy, J.
    Crowley, J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB63 - AB63
  • [34] Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Miller, Megan
    Shen, Y. K.
    You, Yin
    Han, Chenglong
    Gordon, Kenneth B.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (06) : 881 - 890
  • [35] Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
    Kristian Reich
    April W. Armstrong
    Peter Foley
    Michael Song
    Megan Miller
    Y. K. Shen
    Yin You
    Chenglong Han
    Kenneth B. Gordon
    American Journal of Clinical Dermatology, 2020, 21 : 881 - 890
  • [36] Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials
    Papp, Kim
    Crowley, Jeffrey
    Rubel, Diana
    Landells, Ian
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB87 - AB87
  • [37] CONSISTENCY OF RESPONSE BY WEIGHT ACROSS SUBGROUPS OF PATIENTS WITH PSORIASIS TREATED WITH GUSELKUMAB: RESULTS FROM THE VOYAGE 1 AND 2 TRIALS
    Papp, Kim
    Crowley, Jeffrey
    Rubel, Diana
    Landells, Ian
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Thaci, Diamant
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 20 - 20
  • [38] Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials
    Blauvelt, A.
    Reich, K.
    Spelman, L.
    Bagel, J.
    Bissonnette, R.
    Gerdes, S.
    Fakharzadeh, S.
    Song, M.
    Shen, Y. -K.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 52 - 53
  • [39] Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Song, Michael
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Han, Chenglong
    Blauvelt, Andrew
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 848 - 856
  • [40] Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials
    Blauvelt, A.
    Reich, K.
    Spelman, L.
    Bagel, J.
    Bissonnette, R.
    Gerdes, S.
    Fakharzadeh, S.
    Song, M.
    Shen, Y-K
    Gordon, K. B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB38 - AB38
12345